KLYG.. $0.188 Past RR releases not easily avil.On past posts I have made during the past few years.. for futher DD and Research are shown below.. My gut tells me that 2.5 mil. are/is the current rate of sales for the past 12 mo's trailing.. hank
Hopefully KLYG backoff's from today's spike will happen as I now believe that KLYG is no longer a lottery ticket but has a good possibility of becoming a true Micro-cap growth stock.. I will add on any weakness.. Normally close lipped management has come out with New members to the board that will give it exposure thruout the industry which it serves.. Over a year ago a published letter to a respected Nuerosurgeon Journal was written by a respected Nuerosurgeon that seemed to aid in the validity of its procedures and methods of expertise in cranial bone repair.. The new additions to the board will again further their penetration into this new and exciting field.. This Journal Article is contained in a PR below..
I think that with just a few more Qtr's of continued performance a buyout could very well happen and at the least a ten-bagger from this level.. Continued growth and earnings at this rate could very well place KLYG into the high multiple values given medical device companies..
Personally I think KLYG could be a life changing stock for any that continue to own it.. hank
=============================================================
Kelyniam Announces Record Net Income and Additions to the Board of Directors
GlobeNewswire - Jun 03 09:48 EDT
Alert hits:OTC All /kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, June 3, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc, (OTC: KLYG), a prominent manufacturer of custom cranial implants, today reported that the company generated net income of $71,205 in the first quarter of 2014.
Compared with first quarter 2013, net sales increased 23% from $437,415 to $540,286, as a result of increased market penetration, gross profit moved up from $229,027 to $269,788, and net income swung from a loss of $17,272 to a profit of $71,205. Financials will be provided at www.kelyniam.com. "This is the strongest first quarter in the company's history", stated Tennyson Anthony, President and CEO. "Our progress is encouraging and it suggests there is a lot more room for the company to grow. Furthermore, we are working to increase our gross margins throughout 2014."
In addition, the company is excited to announce that the board has appointed Dr. Mark Smith, a prominent Nuerosurgeon, and Dr. Naveh Levy, a practicing Diagnostic Radiologist, to the board of directors.
Mark V Smith, M.D. is a neurosurgeon with over 20 years of clinical experience. He has also worked as a biomedical engineer. He graduated magna cum laude with a bachelor's degree in Electrical Engineering from the University of Maryland in 1980. After working two years as a biomedical engineer, he was admitted to medical school where he earned a doctorate of medicine at the University of Maryland in 1986. He completed his neurosurgery training at SUNY Upstate University Hospital in Syracuse, New York in 1993. He is also fellowship trained in pituitary surgery and epilepsy surgery. Dr. Smith was as an assistant professor of neurological surgery at SUNY Health Sciences Center in Syracuse, New York from 1994 to 1999 specializing in epilepsy and skull base surgery. In 1999 he started a private practice neurosurgery group in Utica, New York. Dr. Smith has received numerous awards and grants and is published in the fields of neuroanatomy, neurophysiology and neurosurgery.
Naveh Levy, M.D. completed his residency at the Cleveland Clinic in 2008 and an MRI Fellowship in 2009 at Michigan State University. He holds a medical degree from George Washington University School of Medicine in Washington, D.C.
"Kelyniam is in the business of taking raw data, a patient's CT scan, and creating a superior product with intricate details for the surgeon to implant in the patient. These new board members bring the technological acumen to complement both aspects of the business," stated Mr Anthony. "We are excited to have them join us."
=============================================================
Kelyniam Global Inc. Revenues Grow 54% from Prior Year
GlobeNewswire - Apr 07 08:30 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, April 7, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc.(OTC: KLYG), a manufacturer of custom cranial implants, announces preliminary revenue of $1,857,516 for 2013. This represents an increase of 54% vs. sales of $1,206,227 in 2012. The Kelyniam product fit and quick turnaround has captured the attention of surgeons throughout the United States. The revenue increase reflects the continued rollout in many additional hospitals. The company will provide financials on their website, kelyniam.com, when they become available in final form from the Accounting Firm.
President and CEO Tennyson S. Anthony stated: "Although we are showing consistent growth and have become a profitable company in a relatively short time, rest assured we are focused on building a company that has the ability to grow at a much greater rate in the near future. My team and I have been working tirelessly to create a company that has the technology, economic fortitude, and operational efficiency to be the market leader in customized implants. We are just starting to see the fruits of our efforts."
=============================================================
Kelyniam Global Inc. Unveils New Product
Canton, CT, April 2, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. has introduced a new product to the marketplace, the "IFS" (Integrated Fixation System) product. The product is patent pending and provides faster implantation, reduced hardware, cost savings and elimination of mundane tasks during the surgical procedure.
The design team at Kelyniam created this product with the surgeons needs in mind together with the realization of economic sensitivities by the hospitals. They carefully collected feedback and input from a multitude of surgeons and designed the product to make their surgeries more efficient.
Kelyniam will be unveiling the new product at the 82nd Annual AANS (American Association of Neurological Surgeons) meeting April 5-9, 2014 in San Francisco.
The company also expects to report financials for 2013 in the coming weeks.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
===================================================================
KLYG.. $0.1388.. I think it's a table pounder but I need to see one more Qtr.. It's been my lottery ticket for 2 years.. Kelyniam Global Inc. turns profitable during the second quarter of 2013
Canton, CT, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG) ("the company") is pleased to announce that it has posted its first ever quarterly profit, for the quarter ending June 30, 2013. Net income for the second quarter was $6,608. Sales in the second quarter were $593,355, up 35% from $438,415 in the first quarter 2013. Year to date sales were $1,031,770, up 253% from the same period in 2012.
The company continues to deploy capital towards marketing and organic growth, and to build market share as its customized PEEK implants are sold in more hospitals than ever. It has recently negotiated better terms for the DECD note secured last year, with the term of the note changing from 5 years to 10 without any increase in the interest rate.
Kelyniam will be an active participant in the Connecticut Economic Trade Mission to Australia later this week, traveling to both Sydney and Canberra, Australia. President & CEO Tennyson Anthony exclaimed, "While we are pleased with our second quarter performance, it is our goal to be used in all 50 states and internationally as well." He continued, "In fact, our growth is not only focused on geography, but on building on our existing products. The company will be announcing a new product in the months to come, one that we feel will turn heads."
The company will be posting the financial tables on the website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
==========================================
KLYG.. $0.1078.. My LOTTERY TICKET,, It moves on air.. Now meeting projections made last year...
Kelyniam Global Inc. Announces Continued Revenue Growth & Approval to Sell Overseas
Canton, CT, May 30, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG), a growing company that designs, manufactures, and sells custom cranial/craniofacial implants, announced today its financial results for the year ending December 31, 2012 and also for the first quarter ended March 31, 2013.
Revenues for the year ending December 31, 2012 totaled $1.2 million. 2012 was the first full calendar year the company had manufactured and sold custom cranial implants in the United States. Revenues for the fourth quarter of 2012 were $414,982 up from $382,177 in the third quarter 2012.
First quarter 2013 revenues were a record $437,415, an increase of 207% from $210,635 in the first quarter of 2012. The increase in sales was attributed to continued marketing and promotional efforts across the United States. The first quarter 2013 marks the first time the company has broken even on an accrual basis.
The 2013 year brings the headwind of the medical device tax to the industry. Beginning Jan 2013 and unless Obamacare is repealed; Kelyniam will be liable for a 2.3% tax on all medical device sales.
A further note: Kelyniam is pleased to announce it has recently been approved to sell its custom cranial/craniofacial implants in Kuwait. It anticipates sales to begin in the coming months.
Related unaudited financial tables will be posted on the company's website www.kelyniam.com.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
Source: Kelyniam Global Inc.
2013 GlobeNewswire, Inc.
---------------------------------------------------
Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center
Canton, CT, Jan. 29, 2013 (GLOBE NEWSWIRE) -- (OTC: KLYG) Kelyniam Custom Cranial Implants, designed to fill the boney void in a patient's skull, have been endorsed by Mario Ammirati, MD, Director of Skull Based Surgery, Stereotactic Radiosurgery and the Dardinger Microneurosurgical Skull Based Laboratory, Wexner Medical Center, at the Ohio State University. This is the first product Dr. Ammirati has ever endorsed.
Dr. Ammirati stated: "As a neurosurgeon specializing in skull based surgery and brain tumors, I am encouraged with the advancements Kelyniam has made in patient customized cranial implants. I am extremely happy with the precision fit and the fast service I receive with every case. Complex cranial defects resulting from trauma or oncologic resection present reconstructive challenges. No matter how complex the defect, Kelyniam's implant design team is very responsive to my needs. They understand the surgical plans and are quick to respond to my design requirements. The end result is a product that fits very well and is quick to implant, thereby reducing O.R. time and providing the patient with excellent aesthetic results."
----------------------------------------
Kelyniam Global Inc. Announces Record Revenues
GlobeNewswire - Jan 15 08:15 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, Jan. 15, 2013 (GLOBE NEWSWIRE) --
Third Quarter
Kelyniam is pleased to announce record quarterly revenues of $382,177 for the third quarter ending September 30th 2012. This represents almost double the product revenue produced in the second quarter 2012. The company continues to penetrate the custom cranial implant marketplace and has sold implants to medical institutions in more than 20 different states. Furthermore, the company has sold the first maxiofacial implants in the fourth quarter as a result of the recent FDA 510k approval in late third quarter.
Fourth Quarter
The debut of Kelyniam maxiofacial implants in the fourth quarter was met with orders. These orders combined with existing custom cranial implant orders propelled revenues to approximately $400,000 for the fourth quarter, exceeding internal expectations of a slow quarter due to multiple holidays and fewer surgeries. Final fourth quarter numbers will be released once a full accounting is complete.
"The final two quarters of the year demonstrate that both the custom cranial and maxiofacial implant markets have capacity for a product of superior design. Management has worked hard to right the ship in 2012 and looks to build on the momentum in 2013" stated President and CEO Tennyson Anthony. "Kelyniam not only has created a product that fills the patient's cranial void, but is filling the void in the marketplace for a timely-delivered well-fitting product."
Upcoming Conference
Kelyniam will be exhibiting once again at the North American Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.
Financial tables can be found on the company's website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
